Patent intelligence · US
US 12263143
Ionic channel modulation as a method for treating tumors through inflammasome activation
Ionic channel modulation as a method for treating tumors through inflammasome activation
Patent details — US 12263143
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 1, 2025
- Expiration
- Mar 27, 2045
- Applicant
- INSTITUT PASTEUR DE MONTEVIDEO
- Claims
- 2
- CPC classes
- A61K, A61K31/138, A61K31/166, A61K31/167
Quick answer
US 12263143 (Ionic channel modulation as a method for treating tumors through inflammasome activation) is held by INSTITUT PASTEUR DE MONTEVIDEO. Status: granted. Granted Apr 1, 2025. Expires Mar 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- INSTITUT PASTEUR DE MONTEVIDEO
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K31/138, A61K31/166, A61K31/167, A61K31/4166, A61K31/496
More from INSTITUT PASTEUR DE MONTEVIDEO
Related pharmaceutical patents in our USPTO index.
-
US 12391663
Isoindolinone compounds
granted -
US 12378199
Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules
granted -
US 12280029
Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
granted -
US 12257247
Targeted degradation of VAV1
granted -
US 12214218
Perfusion modulated tumor dose sculpting with single dose radiotherapy
granted -
US 12070628
Low energy immune priming for treating cancer and metastasis
granted -
US 12011619
Low intensity focused ultrasound for treating cancer and metastasis
granted
Frequently asked questions
What is US patent 12263143?
US 12263143 (Ionic channel modulation as a method for treating tumors through inflammasome activation) is held by INSTITUT PASTEUR DE MONTEVIDEO. Status: granted. Granted Apr 1, 2025. Expires Mar 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12263143?
INSTITUT PASTEUR DE MONTEVIDEO is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 12263143 expire?
Our index shows an expiration date of Mar 27, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.